Literature DB >> 2947363

Expression of HLA antigens on renal tubular cells in culture. I. Evidence that mixed lymphocyte culture supernatants and gamma interferon increase both class I and class II HLA antigens.

G A Bishop, B M Hall, M G Suranyi, D J Tiller, J S Horvath, G G Duggin.   

Abstract

The altered expression of HLA antigens on tissues during rejection is of potential importance to both the initiation and effector arms of the alloimmune response. Associated with rejection episodes, renal tubular cell expression of HLA DR (class II) antigens has been observed to be markedly increased. In this study an in vitro assay using cultured renal tubular cells from normal human kidneys was developed. Monoclonal antibodies to detect HLA DR and HLA A,B,C (class I) molecules were used to identify these antigens on cultured tubular cells either by indirect immunofluorescence stains and flow cytometric analysis or by immunoperoxidase stains with cytological analysis. With these techniques normal cultured cells had little membrane or cytoplasmic HLA DR but did have membrane HLA A,B,C. Culture of renal tubular cells with either supernatants from mixed lymphocyte cultures or purified gamma interferon induced expression of HLA DR, with maximum expression occurring between day 4 and day 6. Increased HLA A,B,C expression was also observed. This increased expression of HLA antigens was shown not to be dependent upon increased cell division of the cultured cells, and removal of gamma interferon from the cultures resulted in a decay in both HLA DR and A,B,C expression within days. HLA expression was inhibited by addition of protein synthesis inhibitor cycloheximide, but not by the addition of puromycin, mitomycin C, or actinomycin D--which suggested that tubular cells had transcribed m RNA for both HLA DR and A,B,C antigens. Expression of HLA antigens was not inhibited by cyclosporine, corticosteroids, or azathioprine. These studies demonstrate that the increased expression of HLA antigens seen in renal allografts at the time of rejection episodes can be explained by the release of lymphokines, especially gamma interferon, by infiltrating cells, and that reduced HLA DR expression of transplanted kidneys in patients treated with cyclosporine is not due to the drug directly inhibiting HLA expression by graft cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2947363     DOI: 10.1097/00007890-198612000-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  A case of atypical hemolytic uremic syndrome in a second renal transplant.

Authors:  Nicholas A Zwang; Bing Ho; Yashpal S Kanwar; Brad Lewis; Matthew Cusick; John J Friedewald; Lorenzo Gallon
Journal:  J Nephrol       Date:  2017-02-21       Impact factor: 3.902

2.  MHC class II in renal tubules plays an essential role in renal fibrosis.

Authors:  Yunfeng Zhou; Zhaokang Luo; Chenghui Liao; Rong Cao; Zain Hussain; Jie Wang; Yeting Zhou; Tie Chen; Jie Sun; Zhong Huang; Baohua Liu; Xiaoyan Zhang; Youfei Guan; Tuo Deng
Journal:  Cell Mol Immunol       Date:  2021-09-23       Impact factor: 11.530

3.  Renal allograft rejection: possible involvement of lymphokine-activated killer cells.

Authors:  J A Kirby; J L Forsythe; G Proud; R M Taylor
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

4.  Primary human adult lung epithelial cells in vitro: response to interferon-gamma and cytomegalovirus.

Authors:  L Ibrahim; M Dominguez; M Yacoub
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

5.  Renal allograft rejection: protection of renal epithelium from natural killer cells by cytokine-induced up-regulation of class I major histocompatibility antigens.

Authors:  Y Lin; G Proud; R M Taylor; J A Kirby
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

6.  Renal allograft rejection: investigation of alloantigen presentation by cultured human renal epithelial cells.

Authors:  J A Kirby; S Ikuta; K Clark; G Proud; T W Lennard; R M Taylor
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.